Betaxolol Market - Size, Share, Outlook, and Forecast till 2026

Betaxolol is a selective beta1 receptor blocker, which is used in the treatment of hypertension and glaucoma. The molecular formula of betaxolol is C18H29NO3. As this compound is selective for beta1 receptors, systemic side effects associated with these are less, as compared to the non-selective beta-blockers. Moreover, betaxolol shows greater affinity for beta1 receptors than metoprolol. Apart from the effects of betaxolol on heart, it also reduces the pressure within the eye. It is achieved through the reduction in production of liquid within the eye. Pressure reduction within the eye reduces the risk of damage to the optic nerve and loss of vision in patients with elevated intraocular pressure due to glaucoma.

Increasing prevalence of diabetes and growing geriatric population are major factors causing the condition of glaucoma, which will, in turn drive growth of betaxolol market. Moreover, enhanced patient awareness programs leads to early diagnosis of diseases such as hypertension and glaucoma followed by treatment, which is further expected to drive growth of betaxolol market

However, patients suffering from sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure cannot use this medicine. This is one of the factors restraining growth of the market.

Key Developments in Betaxolol Market

Key players are adopting various strategies such as mergers, acquisitions, new product launches, expansions, collaborations, partnerships, approvals, and joint ventures to retain its position in the betaxolol market. On June 7, 2018, Bayer completed the acquisition of Monsanto, an agrochemical and agricultural biotechnology corporation.

Moreover, on June 1, 2018, Bayer signed a five-year collaboration agreement with the University of Texas MD Anderson Cancer Center to accelerate the development of novel targeted treatments based on patient or tumor characteristics for, which current therapies have not shown satisfactory clinical efficacy.

On April 12, 2018, GSK signed a strategic agreement with Orchard Therapeutics to transfer its portfolio of approved and investigational rare disease gene therapies to Orchard, securing the continued development of the programs and access for patients.

Some of the major players operating in the betaxolol market include Pfizer Inc., Bayer Healthcare Pharmaceuticals, GlaxoSmithKline Plc., Merck and Company Inc., Syneron Medical Ltd, and Valeant Pharmaceuticals International among others.

Global and Chinese Betaxolol Industry, 2018 Market Research Report

Published Date : May 2018

The 'Global and Chinese Betaxolol Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Betaxolol industry with a focus on the Chinese market. The report provides key statistics on the market status of the Betaxolol manufacturers and is a...


Select Licence :

  • Single User : $4500
  • Multiple User : $7000
  • Corporate User : $10000

Happy To Assist You

Assist you at Worldwide Market Reports

We will be happy to help you find what you need. Please call us or write to us:

Worldwide Market Reports Benefits

Custom Research Solution

Talk to our research consultant to design an exclusive report as per your research needs.

Customer Fulfilment

We aim to fulfil client's research demands with tailored research solutions.

Quick Turnaround Time Reports

We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

360-degree Approach

We cover each industry from supply and demand side with an aim to provide a most holistic research study.